How to Tell If a CBD Product Actually Has THC in It (and Why It's Not Always on the Label)

"CBD only, no THC" is one of the most common claims on hemp products, and it makes sense why people look for it. Maybe you've got a drug test coming up for work, maybe you want to avoid intoxication, or maybe you simply want the product to contain what its label promises. Whatever the reason, "THC-free" feels like a promise. It's worth knowing that it isn't always one.

Pregnancy and breastfeeding are a separate safety question entirely, and worth addressing directly rather than folding into a labeling discussion. The FDA advises avoiding CBD, THC, and marijuana in any form during pregnancy or while breastfeeding. A "THC-free" label or lab result doesn't establish that CBD use itself is safe in that setting - that's a different question than the one this article is about.

This isn't a reason to swear off CBD products entirely, and it's definitely not a reason to feel silly for trusting a label in the first place. Labels exist so people don't have to become chemists just to buy a gummy. The problem isn't that you trusted the label. It's that testing and labeling practices across the market aren't uniform enough to treat every front-label claim as conclusive.

What laboratory testing found

In a 2022 study, Johns Hopkins researchers tested 105 topical CBD products purchased online and from stores in Baltimore in 2020. THC was detected in 37 products, or 35 percent. Of those 37, 19 made no reference to THC on the label and four were explicitly labeled "THC free."

The study documents a real labeling problem, but it doesn't establish that 35 percent of every CBD product sold nationally contains THC. It also looked at topicals specifically, lotions, creams, patches, purchased in one city over a two-month window.

At the time of testing, all of the detected THC concentrations fell below the 0.3 percent delta-9 THC threshold used in the federal definition of hemp. That meant the products didn't exceed that particular controlled-substance threshold, but it didn't establish that every product complied with FDA requirements or applicable state law.

The federal framework is also changing. As of August 2026, the existing 0.3 percent delta-9 THC definition remains in effect, but an amendment to Public Law 119-37 scheduled to take effect November 12, 2026 will apply a total-THC standard and impose a 0.4-milligram-per-container limit on final hemp-derived cannabinoid products. State rules can impose separate or stricter requirements on top of that. Unless Congress changes the law before then, products sold after November 12, 2026 will need to be evaluated under the new federal standard as well as applicable state law.

Why THC can remain in a CBD product

Several manufacturing and labeling factors can contribute:

• Hemp itself isn't THC-free. Even compliant hemp naturally contains trace THC. If a brand isn't testing carefully, that trace amount can end up in the final product without anyone intending it.
• Extraction pulls in more than CBD. Full-spectrum extracts are made to capture a wide range of compounds from the plant, and THC is one of those compounds unless it's specifically filtered out.
• The federal hemp definition isn't a product-approval system. Falling within the federal THC threshold doesn't mean a CBD product has been reviewed or approved by the FDA. Federal law currently doesn't impose one uniform independent-testing and COA requirement on every retail CBD product, although individual states may require testing, labeling, registration, or age restrictions.
• "THC-free" can mean different things in practice. It may reflect a nondetect result at one laboratory's reporting limit, testing on a different batch, or a marketing claim not supported by accessible batch data. Without the underlying report, the label alone doesn't reveal which meaning applies.

None of this means every brand is cutting corners on purpose. A lot of it comes down to how the plant itself works - cannabinoids don't separate out neatly. Producing an extract with no THC detectable at the laboratory's reporting limit requires deliberate purification and validated batch testing, not merely a general "hemp-derived" process. The gap between a brand that does that work, and one that doesn't isn't always visible from the packaging.

What full-spectrum, broad-spectrum, and isolate actually mean

Product terminology offers a clue, but not proof. Full-spectrum CBD generally retains a wider range of hemp compounds and may contain THC. Broad-spectrum products are usually marketed as having THC removed, while CBD isolate is intended to contain purified CBD. Those categories don't replace batch-specific testing, and "broad spectrum" or "isolate" shouldn't be treated as a guaranteed negative drug-test result - they describe intent and formulation approach, not a verified outcome for the exact bottle in your hand.

How to read a COA

A batch-specific Certificate of Analysis, or COA, provides considerably better evidence than a front-label claim. It reports what the laboratory detected in the sample it received, including the cannabinoids tested and their measured concentrations or reporting limits. It's still a laboratory report, though, not an absolute guarantee about every unit produced in that batch.

A few things worth checking when you're looking at one:

1. Does the product name and batch or lot number match the item you're actually holding?
2. Is the laboratory independent, identifiable, and appropriately accredited?
3. Does the cannabinoid panel include delta-9 THC, THCA, and any other relevant THC compounds, not only CBD?
4. Does the report provide detection or quantification limits, so "ND" can be understood as "below the reporting limit" rather than absolute zero?
5. Are the sample and report dates reasonably recent?

Difficulty locating current, batch-specific results is a reason for caution, although it doesn't by itself prove that a product is mislabeled.

What CBD use means for drug testing

This is where the stakes get real for a lot of people. In a 2019 Johns Hopkins study involving six adults, pure CBD taken orally or vaporized didn't produce confirmed positive urine results. After the participants vaporized CBD-dominant cannabis containing 0.39 percent THC, slightly above the federal hemp threshold, two of the six tested positive under commonly used urine-testing standards. The product had a relatively low THC concentration, but the amount inhaled was approximately 3.7 milligrams of THC. The experiment shows that a product with a low THC concentration can still produce a positive result under some conditions, but its size, dose, and inhaled format mean it can't quantify the risk associated with gummies, oils, creams, or every retail CBD product.

No retail "THC-free" claim or COA can guarantee that a person will pass a drug test. Risk depends on the product, dose, frequency of use, route of administration, individual metabolism, and the test's method and cutoff.

If a positive result could affect employment, probation, athletics, custody, or another consequential decision, the lowest-risk approach is to avoid nonprescription CBD and hemp-derived cannabinoid products during the relevant period and confirm the applicable rules with the testing program, supervising authority, clinician, or legal adviser as appropriate. Consumers shouldn't assume that disclosing CBD use will automatically excuse a positive THC result. This matters most in situations like a roadside stop or a post-accident test, where states apply their own marijuana DUI standards - some zero-tolerance, some based on a specific THC threshold - regardless of whether the THC came from an illegal source or a hemp product someone thought was safe. ConsumerShield tracks how these drug-testing and DUI laws vary by state and can connect someone facing that exact situation with an attorney who handles it.

The short version

"THC-free" on a label is a claim, not a guarantee. For an ordinary purchasing decision, checking current, batch-matched lab reports provides better evidence than relying on the front label alone. Accessible results are a positive sign; missing, outdated, or mismatched reports are a reason to look elsewhere.

A COA still cannot guarantee a negative drug test, and it doesn't override the separate advice for pregnancy or breastfeeding. It tells a buyer considerably more about the tested sample, not everything about every unit or every possible consequence of using it.